Dutogliptin tartrate | CAS#890402-81-0 (tartrate) | DPP4 inhibitor

MedKoo Cat#: 319625 | Name: Dutogliptin tartrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dutogliptin, also known as PHX1149, is a selective and orally active DPP4 inhibitor. Dutogliptin improves glycaemic control in patients with type 2 diabetes. PP-4 inhibitors or gliptins, are a class of oral hypoglycemics that block DPP-4. They can be used to treat diabetes mellitus type 2. The first agent of the class - sitagliptin - was approved by the FDA in 2006.

Chemical Structure

Dutogliptin tartrate

CAS#890402-81-0 (tartrate)

Theoretical Analysis

MedKoo Cat#: 319625

Name: Dutogliptin tartrate

CAS#: 890402-81-0 (tartrate)

Chemical Formula: C14H26BN3O9

Exact Mass:

Molecular Weight: 391.18

Elemental Analysis: C, 42.99; H, 6.70; B, 2.76; N, 10.74; O, 36.81

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

852329-66-9 (free base) 890402-81-0 (tartrate)

Synonym

PHX1149; PHX-1149; PHX 1149; Dutogliptin; Dutogliptin tartrate

IUPAC/Chemical Name

(2R,3R)-2,3-dihydroxysuccinic acid compound with ((R)-1-(((R)-pyrrolidin-3-yl)glycyl)pyrrolidin-2-yl)boronic acid (1:1)

InChi Key

SVWHNLVZPGXBNS-MHDNXTQBSA-N

InChi Code

InChI=1S/C10H20BN3O3.C4H6O6/c15-10(7-13-8-3-4-12-6-8)14-5-1-2-9(14)11(16)17;5-1(3(7)8)2(6)4(9)10/h8-9,12-13,16-17H,1-7H2;1-2,5-6H,(H,7,8)(H,9,10)/t8-,9+;1-,2-/m11/s1

SMILES Code

OB([C@H]1N(C(CN[C@H]2CNCC2)=O)CCC1)O.O[C@H]([C@H](C(O)=O)O)C(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Related CAS# 890402-81-0 (tartrate salt); 852329-66-9 (free base).

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 391.18 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014 Jul;24(7):689-97. doi: 10.1016/j.numecd.2014.01.017. Epub 2014 Mar 5. PubMed PMID: 24793580. 2: Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014 Jan;16(1):48-56. doi: 10.1111/dom.12176. Epub 2013 Jul 28. PubMed PMID: 23837679. 3: Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab. 2014 Jan;16(1):30-7. doi: 10.1111/dom.12174. Epub 2013 Jul 16. PubMed PMID: 23803146. 4: Agrawal R, Jain P, Dikshit SN. Ligand-based pharmacophore detection, screening of potential gliptins and docking studies to get effective antidiabetic agents. Comb Chem High Throughput Screen. 2012 Dec;15(10):849-76. PubMed PMID: 23140189. 5: Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther. 2012 Jan;29(1):14-25. doi: 10.1007/s12325-011-0088-z. Epub 2011 Dec 22. Review. PubMed PMID: 22215383. 6: Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin. 2011 Nov;27 Suppl 3:57-64. doi: 10.1185/03007995.2011.602964. PubMed PMID: 22106978. 7: Gallwitz B. Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy. Expert Opin Investig Drugs. 2011 Jun;20(6):723-32. doi: 10.1517/13543784.2011.576667. Epub 2011 Apr 18. Review. PubMed PMID: 21500969. 8: White JR. Alogliptin for the treatment of type 2 diabetes. Drugs Today (Barc). 2011 Feb;47(2):99-107. doi: 10.1358/dot.2011.47.2.1583163. Review. PubMed PMID: 21431099. 9: Li J, Klemm K, O'Farrell AM, Guler HP, Cherrington JM, Schwartz S, Boyea T. Evaluation of the potential for pharmacokinetic and pharmacodynamic interactions between dutogliptin, a novel DPP4 inhibitor, and metformin, in type 2 diabetic patients. Curr Med Res Opin. 2010 Aug;26(8):2003-10. doi: 10.1185/03007995.2010.491266. PubMed PMID: 20583949. 10: Pattzi HM, Pitale S, Alpizar M, Bennett C, O'Farrell AM, Li J, Cherrington JM, Guler HP; PHX1149-PROT202 Study Group. Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55. doi: 10.1111/j.1463-1326.2010.01195.x. PubMed PMID: 20380656. 11: Johnson KM. Dutogliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. Curr Opin Investig Drugs. 2010 Apr;11(4):455-63. Review. PubMed PMID: 20336594. 12: Gale S, Croasdell G. 28th Annual JPMorgan Healthcare Conference--Forest Laboratories and Icagen. IDrugs. 2010 Mar;13(3):145-8. PubMed PMID: 20191426.